Breast Cancer Guide on CD-ROM Is Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

DENVER--The AMC Cancer Research Center, through its Center of Excellence in Health Communications, has developed The Personal Guide to Breast Cancer, a multimedia CD-ROM guide to breast cancer prevention, detection, treatment, and resources, designed to be understood by the average layperson.

DENVER--The AMC Cancer Research Center, through its Center of Excellencein Health Communications, has developed The Personal Guide to BreastCancer, a multimedia CD-ROM guide to breast cancer prevention, detection,treatment, and resources, designed to be understood by the average layperson.

"Audiovisual presentations with full-color photographs guide theviewer through the information, addressing common questions and concerns,"said Bob Baker, president and CEO of AMC.

It is available in English or Spanish, and for Windows or Macintosh.There is a version for home and office use ($29.95, order no. U7AAAO) anda touch-screen version for educational and public-use settings ($49.95,U7AAB8).

The guide is being marketed by Time Life, with a portion of the profitsgoing to AMC. Order by calling Time Life Customer Services at 1-800-846-3843.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content